All Individual Drugs Already Approved

Approved for 30 Other Conditions

No Placebo-Only Group

Pivotal Trial

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibodies given together with combination chemotherapy to see how well they work in treating patients with newly-diagnosed non-Hodgkin's lymphoma.

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Chemotherapy + Monoclonal Antibody Therapy for Non-Hodgkin's Lymphoma

I have never received monoclonal antibody treatment for cancer.

My lymphoma has not spread to my brain or spinal cord.

I have been diagnosed with congestive heart failure.

I have been diagnosed with cardiomyopathy.

I haven't had any cancer in the last 5 years, except for certain skin cancers or cervical pre-cancer.

I have not had radiation therapy for lymphoma.

I have not had chemotherapy for lymphoma before.

My condition is graded between I and III.

I can take care of myself and am up and about more than half of my waking hours.

I have a type of lymphoma that has not been treated and is in an advanced stage.

Cyclophosphamide

Doxorubicin

Rituximab

Tositumomab

Vincristine

Approved for 10 Other Conditions

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen. It is not yet known whether giving triptorelin together with exemestane is more effective than triptorelin and tamoxifen in treating hormone-responsive breast cancer.

PURPOSE: This randomized phase III trial is studying triptorelin and exemestane to see how well they work compared to triptorelin and tamoxifen in treating premenopausal women with hormone-responsive breast cancer.

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Hormone Therapy for Breast Cancer

I don't have any chronic diseases that would interfere with long-term treatment.

I haven't had any cancer except for skin cancer in the last 5 years.

My breast cancer cannot be removed by surgery and has spread to nearby areas.

I have not had chemotherapy before or after surgery.

I haven't had any cancer except certain skin cancers or non-spreading breast cancer in the last 5 years.

My estrogen levels are considered premenopausal after surgery.

I have never had a blood clot or if I did, my doctor says it's okay.

My breast cancer diagnosis was confirmed through tissue examination.

My cancer has not spread to distant parts of my body.

I have had breast cancer in either the same or the opposite breast before.

I do not have liver disease that would interfere with long-term monitoring.

I do not have kidney disease that would interfere with long-term monitoring.

I am not taking any estrogen, progesterone, or androgen treatments.

I am not taking any other aromatase inhibitors.

I don't have any lung diseases that would interfere with long-term monitoring.

I am fertile and not using birth control methods that don't involve hormones.

I haven't had hormone therapy for breast cancer since diagnosis.

I have never had radiation therapy for ovarian cancer.

I am not currently taking bisphosphonates, or I meet the specific criteria for their use.

I haven't used tamoxifen, SERMs, or hormone therapy for over a year before my breast cancer diagnosis.

I am not currently on any oral or patch-based hormone treatments.

I have not had both of my ovaries removed.

I do not have any detectable cancer in the lymph nodes under my arm.

I am a woman who has not gone through menopause.

I have had surgery to remove lymph nodes under my arm or a biopsy that was negative.

I am not using any hormonal contraceptives.

My cancer is only in my breast and nearby lymph nodes.

My cancer was entirely removed by surgery.

I don't have heart disease that would interfere with long-term monitoring.

I have had surgery or radiation on the lymph nodes under my arm due to cancer.

My cancer is positive for estrogen or progesterone.

I have had a condition where my lymphocytes grow abnormally.

I have never had invasive breast cancer before.

Exemestane

Tamoxifen

Triptorelin

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating resected breast cancer.

PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination chemotherapy to see how well they work in treating patients who have undergone surgery for stage I, stage II, or stage III breast cancer.

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Chemotherapy for Breast Cancer

I have had surgery to remove breast cancer and affected lymph nodes.

I haven't had cancer in the past 5 years, except for certain skin cancers or early-stage cervical or breast cancer.

My cancer is at an early or mid-stage and can be operated on.

I know my cancer's estrogen and progesterone receptor status.

My tumor is smaller than 1 cm and doesn't meet certain criteria.

I have breast cancer in both breasts, diagnosed within a month of each other, and the more advanced tumor meets the study criteria.

My breast cancer is confirmed and not spread beyond stage III.

My tumor is larger than 2 cm or larger than 1 cm with specific features.

My cancer has not spread to my lymph nodes and my tumor is at least 1 cm with high-risk features or larger than 2 cm.

My cancer has not spread to nearby tissues.

My breast cancer has not spread to underarm or breast nodes.

My breast cancer has spread to my lymph nodes.

Doxorubicin Hydrochloride

Paclitaxel

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether androgen-ablation therapy is more effective with or without docetaxel in treating metastatic prostate cancer.

PURPOSE: This randomized phase III trial is studying androgen-ablation therapy and chemotherapy to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Androgen Ablation Therapy + Chemotherapy for Prostate Cancer

Androgen-deprivation therapy

Docetaxel

This randomized phase III trial studies the best individual therapy for women who have node-negative, estrogen-receptor positive breast cancer by using a special test (Oncotype DX), and whether hormone therapy alone or hormone therapy together with combination chemotherapy is better for women who have an Oncotype DX recurrence score of 11-25. Estrogen can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving hormone therapy together with more than one chemotherapy drug (combination chemotherapy) has been shown to reduce the chance of breast cancer recurrence, but the benefit of adding chemotherapy to hormone therapy for women with node-negative, estrogen-receptor positive breast cancer is small. New tests may provide information about which patients are more likely to benefit from chemotherapy.

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Hormone Therapy + Chemotherapy for Breast Cancer

I am receiving treatment for chronic obstructive pulmonary disease.

I am a woman who can have children and am not using birth control.

I had an Oncotype DX test, but my recurrence score wasn't between 11-25.

My cancer is positive for estrogen and/or progesterone receptors.

I have heart issues that prevent me from using certain cancer drugs.

I have had surgery that meets the trial's requirements.

I haven't had chemotherapy or radiation for my cancer.

My tumor is between 5 mm and 5 cm, possibly with aggressive features.

My doctor and I agree to start standard chemotherapy and hormonal therapy after surgery.

I have a breast cancer tissue sample ready for testing.

I have been cancer-free from any previous cancers for at least 5 years.

Anastrozole

Combination Chemotherapy

Letrozole

Tamoxifen Citrate

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Fluorouracil may also make tumor cells more sensitive to radiation therapy. Leucovorin calcium may protect normal cells from the side effects of chemotherapy, and it may help fluorouracil work better by making tumor cells more sensitive to the drug. Giving radiation therapy together with chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase II trial is studying how well giving radiation therapy together with fluorouracil with or without combination therapy works in treating patients who are undergoing surgery for stage II or stage III rectal cancer.

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Radiation Therapy + Fluorouracil for Rectal Cancer

This trial tests if combining radiation therapy with chemotherapy can shrink tumors in patients with stage II or III rectal cancer. The treatment aims to make tumors smaller and easier to remove while protecting normal cells. The study will also look at the timing of treatments and their effects on surgery and recovery.

I am allergic to 5-fluorouracil, leucovorin, or oxaliplatin.

I do not have any mental health conditions that would affect my ability to follow study rules.

My blood, liver, and kidney tests are normal.

My cancer has spread to other parts of my body.

My rectal cancer is confirmed and is within 12 cm from the anal opening.

I can be part of the study if MRI can stage my condition due to a high-grade obstruction.

I have hereditary non-polyposis colorectal cancer and meet other study requirements.

I have trouble taking or absorbing pills.

My rectal cancer has come back in the same area.

I have a serious heart condition or had a heart attack in the last 6 months.

I have colorectal cancer and am being treated for rectal cancer as per the study's guidelines.

I had cancer before, but it was treated and I've been cancer-free for over 5 years.

I am fully active or able to carry out light work.

My cancer is at Stage II or III, and may have spread to nearby organs.

I have had radiation therapy to my pelvis before.

I have a history of inflammatory bowel disease.

I have a history of Familial Adenomatous Polyposis.

I have no history of uncontrolled seizures or major brain disorders.

Conventional Surgery

Fluorouracil

Leucovorin Calcium

Oxaliplatin

Radiation Therapy

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer.

PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer.

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

Letrozole for Hormone Receptor-Positive Breast Cancer

You cannot participate in this study if you have any of the following conditions:

You have had a bone fracture in your wrist, hip, or spine that was not caused by an injury.

If you have high cholesterol, you must have it under control with medication or lifestyle changes for at least one year. If you have a history of diabetes, high blood pressure, obesity, smoking, high triglycerides, heart disease, or a family history of early-onset heart disease, you may not be eligible to participate.

You have had another type of cancer in the past, but you are considered to be cured for at least 5 years, and your doctor believes the cancer is unlikely to come back. However, if you had certain types of non-invasive cancers in the past 5 years, you may still be eligible.

Placebo

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin and leuprolide, may stop the adrenal glands from making androgens. Giving docetaxel and leuprolide or goserelin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether giving docetaxel and leuprolide or goserelin before surgery is more effective than surgery alone in treating patients with prostate cancer.

PURPOSE: This randomized phase III trial is studying docetaxel and leuprolide or goserelin to see how well they work when given before surgery compared with surgery alone in treating patients with high-risk localized prostate cancer.

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Chemotherapy + Hormone Therapy With Surgery for Prostate Cancer

I have a history of blood clots or stroke and cannot undergo major prostate surgery.

I am able to get out of my bed or chair and move around.

I have not had any cancer except for basal or squamous cell skin cancer in the last 5 years.

My cancer is not small cell, neuroendocrine, or transitional cell carcinoma.

I need assistance with my daily activities due to my health condition.

My cancer is in an early stage and has not spread, as confirmed by scans.

I am a good candidate for prostate surgery and expected to live more than 10 years.

I have a history of blood clots but am considered fit for prostate surgery.

My cancer is confirmed as prostate adenocarcinoma.

My prostate cancer is aggressive, with a high Gleason score or a low chance of being progression-free in 5 years.

I have prostate cancer and haven't had surgery, radiation, or chemo, but may have had up to 4 months of hormone therapy.

My prostate cancer's aggressiveness has been measured.

I have had a condition where my lymphocytes multiply unusually.

Goserelin

Leuprolide

Surgery

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, and luteinizing hormone-releasing hormone agonist, may lessen the amount of androgens made by the body. It is not yet known which regimen of radiation therapy with or without androgen-deprivation therapy is more effective for prostate cancer.

PURPOSE: This randomized phase III trial is studying prostate radiation therapy to see how well it works compared with short-term androgen deprivation therapy given together with pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer.

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Radiation Therapy + Androgen Deprivation for Prostate Cancer

This study is evaluating whether radiation therapy is more effective than short-term androgen deprivation therapy for prostate cancer.

I have a lump in the prostate area that might indicate cancer has returned.

I received chemotherapy before or after my prostate surgery.

I have not had certain cancer treatments like cryosurgery or radiation in the pelvic area recently.

My prostate cancer was treated with surgery and either no lymph nodes were affected or their status is unknown.

My PSA levels are between 0.1 and 2.0 ng/mL after my prostate surgery.

My testosterone levels are within the normal range.

My cancer has not spread to my pelvic lymph nodes or any enlarged nodes have tested negative.

I am undergoing or have undergone hormone therapy for cancer.

LHRH agonist

Pelvic Lymph Node Radiation Therapy

Prostate Radiation Therapy

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Radiation + Chemotherapy for Small Cell Lung Cancer

My cancer is confined to one side of my chest and has spread only to nearby lymph nodes.

I have had only one round of chemotherapy that included carboplatin or cisplatin and etoposide.

I have not had surgery to completely remove my cancer.

My lung cancer diagnosis was confirmed through lab tests.

I have a tumor that can be measured by scans.

I do not have fluid in my lungs or, if I do, it has been tested and is not cancerous.

I haven't had chemo or radiation for small cell lung cancer, except as noted before.

My kidney function, measured by creatinine levels or clearance, is within the required range.

My cancer has spread to lymph nodes above my collarbone or on the opposite side of my chest.

You have a certain type of white blood cells called granulocytes, and you need to have at least 1,500 of them in a tiny drop of blood.

Your AST (SGOT) level is not more than 2 times the upper limit of normal.

Your blood platelet count is at least 100,000 per microliter.

I have not had radiation therapy to my chest area.

I do not have cancer cells in my chest or heart fluid.

I can care for myself and am up and about more than 50% of my waking hours.

Your total bilirubin level is not more than 1.5 times the upper limit of normal.

Carboplatin

Cisplatin

Etoposide

High Radiation Dose Therapy

Standard Radiation Dose Therapy

This randomized phase III trial studies radiation therapy to see how well it works with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether radiation therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ.

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Radiation Therapy + Trastuzumab for Breast Cancer

I am fully active or restricted in physically strenuous activity but can do light work.

I have been cancer-free for over 5 years and at low risk of it coming back.

I have suspicious masses or calcifications that have not been biopsied.

Siteman Cancer Center Clinical Trials 2022

Trials at this site

Is this your site?

Is this your site?

Patient Reviews